Bolt Biotherapeutics is a clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) for solid tumor cancer treatment, utilizing its proprietary Boltbody platform to create therapies that link tumor-targeting antibodies with immune-stimulating agents
Bolt Biotherapeutics is a clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) for solid tumor cancer treatment, utilizing its proprietary Boltbody platform to create therapies that link tumor-targeting antibodies with immune-stimulating agents.